Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.38 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.38 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.33 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.32 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758619 | 0.98 | TSHR (0.59) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Hydrochloric Acid SCHEMBL6300759 | 0.96 | TSHR (0.53) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Iodide SCHEMBL1255392 | 0.96 | TSHR (0.57) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Hydrochloric Acid SCHEMBL204258 | 0.96 | TSHR (0.57) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Fluoride Ion SCHEMBL1254970 | 0.96 | TSHR (0.57) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Bromide SCHEMBL1254317 | 0.96 | TSHR (0.57) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Chloromethane SCHEMBL10796929 | 0.94 | TSHR (0.55) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Acetic Acid SCHEMBL22188618 | 0.93 | TSHR (0.53) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Sulfuric Acid SCHEMBL8098694 | 0.90 | TSHR (0.50) | TSHRTHRBMAPTSLC22A16CHRM2 | |
| Phosphoric Acid SCHEMBL8763237 | 0.90 | TSHR (0.50) | TSHRTHRBMAPTSLC22A16CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264486-B1 | Ophthalmic, tinted molding composition, molding having high Dk-value and method of its production | NOVARTIS AG (CH) | 2018-08-22 | — | — | EP | claimed |
| US-8361492-B2 | Drug delivery system and methods of use | Ocugenics, LLC (US) | 2013-01-29 | — | — | US | claimed |
| EP-2413917-A2 | DRUG DELIVERY SYSTEM AND METHODS OF USE | Ocugenics, Llc (US) | 2012-02-08 | — | — | EP | claimed |
| JP-4638127-B2 | — | — | 2011-02-23 | — | — | JP | claimed |
| EP-2264486-A2 | Ophthalmic molding composition | Novartis AG (CH) | 2010-12-22 | — | — | EP | claimed |
| US-7847016-B2 | Tinted, high DK ophthalmic molding and a method for making same | NOVARTIS AG (CH) | 2010-12-07 | — | — | US | claimed |
| WO-2010120489-A2 | DRUG DELIVERY SYSTEM AND METHODS OF USE | Ocugenics, LLC (US) | 2010-10-21 | — | — | WO | claimed |
| US-20090269392-A1 | Drug Delivery System And Methods Of Use | Ocugenics, LLC | 2009-10-29 | — | — | US | claimed |
| US-20090096985-A1 | Tinted, high DK ophthalmic molding and a method for making same | ALCON INC. (CH) | 2009-04-16 | — | — | US | claimed |
| JP-2004517360-A | — | — | 2004-06-10 | — | — | JP | claimed |
| EP-1360527-A2 | A TINTED, HIGH DK OPHTHALMIC MOLDING AND A METHOD FOR MAKING SAME | Novartis AG (CH) | 2003-11-12 | — | — | EP | claimed |
| WO-2002054136-A2 | A TINTED, HIGH DK OPHTHALMIC MOLDING AND A METHOD FOR MAKING SAME | NOVARTIS AG (CH) | 2002-07-11 | — | — | WO | claimed |
| EP-2951242-B1 | WATER SOLUBLE SILICONE MATERIAL | MOMENTIVE PERFORMANCE MAT INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10118994-B2 | Water soluble silicone material | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-2264486-B1 | Ophthalmic, tinted molding composition, molding having high Dk-value and method of its production | NOVARTIS AG (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9956168-B2 | Extended release drug-delivery contact lenses and methods of making | MERCY MEDICAL RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| EP-0819258-A1 | EXTENDED WEAR OPHTHALMIC LENS | Novartis AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| WO-1997022019-A1 | METHODS OF MANUFACTURING CONTACT LENSES | NOVARTIS AG (CH) | 1997-06-19 | — | — | WO | disclosed |
| WO-1996036890-A1 | POLYSILOXANE-POLYOL MACROMERS, THEIR PREPARATION AND THEIR USE | NOVARTIS AG (CH) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996031792-A1 | EXTENDED WEAR OPHTHALMIC LENS | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | disclosed |